Login to Your Account

Pharma: Clinic Roundup

Friday, October 4, 2013
Abbvie Inc., of Chicago, shared results of a posthoc analysis of a Phase II study of Humira (adalimumab) for patients with hidradenitis suppurativa. The analysis showed that Humira produced a significant response rate in patients with moderate to severe disease at 16 weeks compared to placebo for the two dosing regimens assessed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription